New cocktail hopes to tame tough pancreatic cancer
NCT ID NCT05026905
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This phase II trial is testing two different drug combinations for people with metastatic pancreatic cancer that has spread. One group gets a standard chemo plus S-1 and leucovorin; the other gets standard chemo plus oxaliplatin. The goal is to see which combo works better at shrinking tumors and delaying progression. About 66 participants are enrolled across multiple centers in Taiwan.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- gemcitabine, nab-paclitaxel, S-1, leucovorin, oxaliplatin
- What this could lead to
- If successful, this could point toward a more effective first-line treatment for metastatic pancreatic cancer, potentially extending the time patients live without the disease worsening.
- What could go wrong
- This is a small, early-phase trial (66 participants) testing two experimental combinations. The results may not lead to a new standard of care, and the added drugs could increase side effects without improving survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 66 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2021
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * A.Cytology or histology confirmed pancreatic adenocarcinoma with evidence of distant metastasis.Mixed component of other cell type (eg, adenosquamous, adenocarcinoma with neuroendocrine differentiation) is eligible but should notify PI before registration. * B.No history of prior chemotherapy for pancreatic cancer, except adjuvant chemotherapy that completed at least 6 months before documentation of recurrence by imaging study. * C.Patients with prior radiotherapy are eligible if there are other measurable target lesions that is not irradiated. * D.At least one measurable lesion according to RECIST version 1.1 * E.Ability to understand and willingness to sign a written informed consent document. * F.ECOG performance status 0-1 * G.Age of 20 years or above * H.Adequate organ function as defined by the following criteria: absolute neutrophil count (ANC) ≥ 1,500/mm3 hemoglobin level ≥ 9 g/dL platelet count ≥ 100,000/mm3 total bilirubin ≤ 2 ULN or ≤5 ULN if caused by biliary obstruction and achieving adequate drainage judged by investigator aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤ 3 x ULN or ≤ 5.0×ULN in the presence of liver metastases creatinine clearance rate (CCr) ≥ 50 mL/min (24-hour urine collection or calculated by Cockroft-Gault formula; male: \[(140 - age) × weight (kg)\]/\[72 × serum creatinine(mg/dL)\];female=male x 0.85 -I.Patients with childbearing potential shall have effective contraception for both the patient and his or her partner during the study. Exclusion Criteria: * A. Other malignancy within the past 5 years except for adequately treated localized cancer or carcinoma in situ;All patients with other malignancy within the past 5 years should notify PI before registration. * B.Active or uncontrolled infection; * C.Significant medical conditions that is contraindicated to study medication or render patient at high risk from treatment complications at physician discretion * D.Pregnant women or nursing mothers, or positive pregnancy test for women of childbearing potential. * E.History of active autoimmune disease within 3 years or use of steroid more than prednisolone 10mg/day.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic pancreatic adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China Medical University Hospital
Taichung, 400, Taiwan
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 800, Taiwan
-
National Cheng Kung University Hospital
Tainan, 600, Taiwan
-
Taichung Veterans General Hospital
Taichung, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo tested against aggressive pancreatic cancer
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors